3710Fast Delivery LL-37 High Qulity CN Manufacturer Supply
TDS 21 Inquiries
1415456-99-3
Pharmaceutical Grade
99.976%
HK
Henghong Biotechnology
10mg*/vials/box
Yes
2026-09-10
Tirzepatide,Retatrutide,GHK-CU,KPV,MOTS-C,KLOW80
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Cagrilintide is a long-acting amylin analog and peptide-based pharmaceutical ingredient. As a pharmaceutical raw material, Cagrilintide is characterized by its peptide structure and amylin receptor activity. It is suitable for API research, analytical testing, pharmaceutical development, and related manufacturing processes.
CertificatesBasic Info-
Product Name:
Cagrilintide
Other Name:Cagrilitide、Cagrilintide acetate、Caglitide、Kagliptin、Cargliptin、Cargilinitide
CAS No.:1415456-99-3
Molecular Formula:C194H312N54O59S2
Molecular Weight:0
EC Number:206-141-6
Color/Form:White to off-white
Categories:
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,GHK-CU,KPV,MOTS-C,KLOW80
-
Location:
2nd Floor, Room 0996, No. 963 Tianyuan Road, Tianhe District, Guangzhou
-
Average lead Time:
5 days
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
-
Inquiry History21 Inquiries
Country Product Purchase Quantity Date Posted
France
Cagrilintide
10 MG May 22, 2026
United States
Cagrillintide Lyophilized powder
1000 MG Apr 20, 2024
United States
Cagrilintide
10 MG Sep 23, 2026
United States
Cagrilintide
25 MG Aug 31, 2026
United Kingdom
cagrilintrude
20 MG Jul 21, 2026
United States
Cagrilintide
1 KG Jul 17, 2026
United States
Cagrilintide
30 MG May 26, 2026
United States
Cargrilintide
10 MG Mar 19, 2026
United Kingdom
cagrilintide
10 MG Feb 18, 2026
United States
Cagrilintide
20 MG Dec 19, 2025
United Kingdom
Cagrilintide
100 MG Dec 10, 2025
Germany
CAGRILINTIDE
50 MG Sep 21, 2026
United States
Cagrilintide
10 MG Jul 13, 2026
Ghana
carigrilintide
10 MG Feb 9, 2026
United States
Cagrilintide
20 MG Jan 13, 2026
United States
Cagrilintide
1 KG Dec 15, 2025
United States
Cagrilintide
1 KG Oct 11, 2025
United States
Cagrilintide
10 MG Jul 3, 2025
United States
Cagrilintide
1 G Jun 16, 2025
United States
Cagriliniitde
1 Jan 24, 2025 Post an enquiry for this product
More from this Seller
-
-
-
SHBMixed liquid, directly supplied by the factory, with reasonable price
Pharmaceutical Grade / 99.3%
-
-
-
-
HHB solution, directly supplied by the factory, with reasonable price
Pharmaceutical Grade / 99.6%
-
-
-
-
CP10 Factory Supply | Research Peptide | 99% Purity | Lyophilized Powder
Pharmaceutical Grade / 99.97%
-
